MedPath

A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study on Effects of Daily Ingestion of Green Tea Containing Polyphenol to Reduce Body Fat Percentage

Not Applicable
Conditions
Healthy adults
Registration Number
JPRN-UMIN000020824
Lead Sponsor
Hokkaido Information University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
190
Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects who are under treatment and medication for obese, hyperlipidemia and diabetes. 2.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, disorder of endocrine and metabolism or affected with infectious diseases which are required to report to the authorities. 3.Subjects who use pacemaker or defibrillator. 4.Subjects who have a major surgical history related to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 5.Subjects with unusually high and/or low blood pressure or abnormal hematological data. 6.Subjects with serious anemia. 7.Pre- or post-menopausal women having obvious changes in physical condition. 8.Subjects who are at risk of having allergic reactions to drugs or foods (especially tea). 9.Subjects who have largely changed their dietary habits, physical activity habits and/or BW within the last 6 months. 10.Subjects who regularly take drugs, functional foods and/or supplements which would affect BW and BFP. 11.Subjects who regularly take drugs, functional foods and/or supplements (EPA, DHA, MCT, phytosterol, sesamin, turmeric, polyphenols and dietary fiber such as indigestible dextrin, etc.) which would affect the blood lipid levels. 12.Subjects who regularly take drugs, functional foods and/or supplements (containing dietary fiber such as indigestible dextrin, polyphenol, etc.) which would affect blood glucose. 13. Heavy smokers, alcohol addicts or subjects with irregular lifestyle 14. Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to this study. 15. Pregnant or lactating women or women expect to be pregnant during the clinical trial. 16. Subjects who participate in other clinical trials within the last one month prior to this study. 17. Any other medical reasons judged by the principal investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath